Past Studies

Consciousness and Psilocybin Effects on Well-Being (The CoPE Study) Pilot Phase

Sponsor: Tiny Blue Dot Foundation

Principal Investigator: Charles Raison, MD

Site: UW-Madison

Timeframe: November 2023 – February 2025

Purpose: The purpose of this phase 1 study was to identify a dosing strategy that would allow IV psilocybin to be administered to sleeping subjects without awakening them. The pilot study is part of a larger investigation to examine whether conscious awareness during the psychedelic experience is required (or strongly beneficial) for the longer-term effects on Perception Box expansion. Refer to the CoPEWell study under the Current Studies tab.

Results: The team is currently analyzing the data and synthesizing a paper from this recent study. Please check back when we have published these results.

Clinicaltrials.gov Summary

Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study) Pilot Phase

Sponsor: Mike & Mary Shannon / UW Foundation

Principle Investigator: Christopher Nicholas, PhD

Site: UW- Madison

Timeframe: May 2021 – November 2022

Purpose:  The purpose of this phase 1 study was to determine the optimal dose of midazolam that allowed a psychedelic experience while inducing amnesia for the experience. This pilot is part of a larger investigation on the role played by memory and conscious perception for the psychedelic experience in the antidepressant effects of psilocybin. Refer to the RECAP2 Study under the Current Studies tab.

Results: Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience

Clinicaltrials.gov Summary

A Study of Psilocybin for Major Depressive Disorder (MDD)

Sponsor: Usona Institute

Principle Investigator: Charles Raison, MD

Sites: 11 U.S. sites (see publication below)

Timeframe: December 2019 – June 2022

Purpose: The purpose of this phase 2 clinical trial was to evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with major depressive disorder (MDD).

Results: Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Clinicaltrials.gov Summary

 

For more information on previous research, please review the Investigator’s and Co-Investigators’ publications on Google Scholar.